NIH Highlighted Topic: Building Health through Multidomain Resilience Research from Molecules to Communities
Highlighted Topic 117 | Participating ICOs: NHLBI, NCCIH, NCI, NIA, NIAAA, NIMHD, OBSSR, ODP, ODS, ORWH, THRO | Posted August 28, 2026 | Expires August 25, 2028 | Apply through the NIH SBIR parent announcement (PA-27-100) or the NIH STTR parent announcement (PA-27-102).
Executive Summary
NIH has designated multidomain resilience research as a formal Highlighted Topic, with eleven Institutes, Centers, and Offices publishing their own areas of interest, spanning cardiopulmonary health, cancer, aging, alcohol use, minority health and health disparities, integrative health, dietary supplements, women's health, autoimmunity, disease prevention, behavioral science, and tribal health.
The framing is a genuine inversion of how most biomedical research is funded. Rather than asking why people get sick, NIH is asking why some people do not get sick despite carrying known risk. NHLBI illustrates it with four cases that make the concept concrete: hypertension without stroke, full recovery after heart valve surgery, preserved lung function despite tobacco exposure, and the interplay of resilience with sickle cell disease exacerbation such as vaso-occlusive crises. Resilience, in NIH's working definition, is a living system's capacity to resist, recover, adapt, or grow from challenges or stressors, tracked over time across interconnected individual, community, and environmental systems.
NIH also says plainly what has been holding the field back: heterogeneous definitions, models, and measures. That diagnosis is the opportunity. The named high-priority research areas are developing and refining resilience measures and metrics, data interoperability, mechanistic understanding of protective and restoring factors distinct from disease-risk reduction, and identifying biomarkers that reflect or predict resilience. Three of those four are measurement and infrastructure problems, which is to say they are product problems.
For a small business, the concentrated openings are validated resilience measurement instruments and digital assessments, biomarker panels that predict recovery capacity rather than disease risk, controlled-perturbation and challenge-recovery testing protocols paired with longitudinal monitoring hardware, multisystem phenotyping analytics, and data interoperability and federated analysis platforms. NIA in particular asks for dynamic resilience measures using controlled perturbations and longitudinal monitoring, plus advanced analytics for multisystem resilience phenotyping, which reads as an instrument-plus-software specification rather than a research question.
There is no dedicated funding and no separate application. A Highlighted Topic is a priority signal, not a Notice of Funding Opportunity. You apply through the standard NIH SBIR or STTR omnibus and compete in the normal pool, and NIH states that applying in a Highlighted Topic area will not affect referral or review. NIMHD states it may dedicate available funds to this topic area and may give special consideration to meritorious applications in it. NCCIH states it may give special consideration. The other participating ICOs make no such statement.
One structural trap to notice immediately. Of the eleven participating ICOs, five do not award grants: OBSSR, ODP, ODS, ORWH, and THRO. Two of those five, ODS and ORWH, published the most commercially concrete interests on the entire page, dietary supplement resilience biomarkers and federated data platforms respectively. Your application still has to land on the mission of one of the six that write checks: NHLBI, NCCIH, NCI, NIA, NIAAA, or NIMHD.
Under the current SBIR parent announcement, standard budget guidelines run up to $323,090 for Phase I and up to $2,153,927 for Phase II, and NIA is approved to exceed both. The next standard receipt dates are September 5, 2026, January 5, 2027, and April 5, 2027, and the topic stays live through August 25, 2028.
A Quick Note on the NIH SBIR and STTR Program
The NIH, CDC, and FDA SBIR and STTR programs are the largest source of non-dilutive early-stage funding for health, biomedical, and life science technology in the United States. NIH alone sets aside well over a billion dollars a year. Awards are grants, not investments. No equity, no repayment, no board seat.
The program runs in phases. Phase I funds proof of concept and feasibility. Phase II funds the substantive research and development that turns a validated concept into a product. Fast-Track combines both in one application, and Direct to Phase II lets companies that have already established feasibility skip Phase I. Phase IIB and the Commercialization Readiness Pilot extend funding for late-stage work such as validation, scale-up, and regulatory submissions. Applicants must be for-profit U.S. small businesses with 500 or fewer employees and majority U.S. ownership.
For the complete breakdown of the NIH SBIR and STTR program, including all budget caps by Institute, clinical trial policies, eligibility mechanics, review criteria, and the full timeline, see our full executive summary here: NIH, CDC and FDA Parent SBIR Grant (PA-27-100).
Everything below is specific to this Highlighted Topic.
What Is a Highlighted Topic, and How Is It Different From a Funding Opportunity?
A Notice of Funding Opportunity (NOFO) is a solicitation. It has an announcement number, its own application package, its own review criteria, and usually its own set-aside funding. You apply to it directly.
A Highlighted Topic is a published statement of scientific priority maintained centrally by NIH. It has no application package and no guaranteed funding. You cannot apply to it. You apply through a broad opportunity such as the SBIR or STTR parent announcement, and the topic tells you what the participating ICOs want to fund inside their existing budgets.
NIH is explicit about how this works:
Apply through an appropriate parent announcement or other broad NIH opportunity.
Reach out early to the listed scientific contacts to discuss alignment.
If an ICO chooses to dedicate funding to a topic, the amount depends on available funds, the number of meritorious applications, and competing priorities.
Applying in a Highlighted Topic area will not affect NIH referral or review of your application.
NIH reviews each topic annually for continued alignment and Institutes can post or retire topics at any time, so verify the topic is still live before each cycle you plan to submit in.
There is no notice number to enter in the Agency Routing Identifier field, unlike the older Notice of Special Interest model. Make the alignment explicit in your cover letter and Specific Aims, and confirm handling with your target Institute's program officer before you submit.
In this particular topic, the map matters more than usual. Resilience is not a study section. There is no established review culture for it, six different Institutes could plausibly claim the same project, and NIH has openly acknowledged the field lacks harmonized terminology. That combination means the Institute you land at will substantially determine how your application is read.
What Are They Looking For? A Detailed Overview
The Stated Purpose
The topic aims to accelerate rigorous, reproducible, interdisciplinary resilience science to promote health and well-being across the lifespan and across populations. NIH describes resilience mechanisms as operating across scales and domains to maintain health, enabling prevention and recovery from chronic and acute disease despite known risk factors.
The focus is research on:
Protective pathways and their biological mechanisms that maintain physiological function throughout the life course
Harmonized terminology
Standardized protocols
Validated measures and biomarkers
Implementation science to optimize evidence-based interventions, including lifestyle interventions, across populations
NIH specifically names children, tribal communities, and groups at risk for health disparities as populations of interest.
How NIH Defines Resilience
NIH uses a broad definition: a living system's capacity to resist, recover, adapt, or grow from challenges or stressors, with outcomes tracked over time across interconnected individual, community, and environmental systems. NIH attributes this framing to Brown and colleagues, 2023.
Those four verbs are not interchangeable and they are worth treating as a menu. Resistance means the stressor lands and nothing breaks. Recovery means function returns to baseline. Adaptation means the system reorganizes to a new functional state. Growth means it ends up better than before. A well-constructed application picks one and measures it, rather than gesturing at resilience generally.
The Background Problem NIH Wants Solved
NIH states that resilience spans whole-person systems, integrating molecular, cellular, physiological, and psychological levels within social communities and environmental contexts, and that translating this multiscale, multidomain nature has been limited by heterogeneous definitions, models, and measures.
The named high-priority research areas follow directly from that:
Developing and refining resilience measures and metrics
Data interoperability
Advancing mechanistic understanding of protective and restoring factors distinct from disease-risk reduction
Identifying biomarkers that reflect or predict resilience
The Structural Requirement That Decides Most Applications
This is the single most actionable sentence in the topic, and it functions as a checklist. NIH states that aligned applications would:
Define the challenge or stressor
Define the system or systems
Define the resilience response or outcome
Include at least one domain of analysis, preferably across domains, to accelerate translation into implementable prevention, treatment, and recovery strategies
Applications that skip step one are the most common failure mode in resilience science. Without a specified stressor there is no resilience to measure, only cross-sectional association. If you write to this topic, name the stressor explicitly and early, and design so that it is either naturally occurring and documented or experimentally applied.
The Distinction That Separates Real Responsiveness From Repackaging
Note carefully the phrase "distinct from disease-risk reduction." NIH is drawing a line, and reviewers will apply it.
Lowering someone's blood pressure reduces disease risk. Understanding why a hypertensive person never has a stroke is resilience. Reducing tobacco exposure reduces risk. Understanding why some heavy smokers preserve lung function is resilience. A number of companies will reframe an existing risk-reduction product as resilience-promoting for this cycle. That reframing is visible, and it will be scored accordingly. The test is whether your work explains or enhances maintenance of health in the continued presence of risk rather than removal of the risk.
A Methodological Signal Worth Reading Twice
Both NIA and ODS ask for controlled perturbations and challenge-recovery designs with repeated measures. That is a design requirement, not a stylistic preference. A stressor is applied or occurs, and the system is measured before, during, and after. Cross-sectional designs cannot capture resist, recover, adapt, or grow, because all four are trajectories.
For a company, this is actually favorable. Challenge-recovery designs with longitudinal monitoring are exactly where instrumentation, wearables, remote monitoring, and analytics create value, and they are exactly what a purely observational cohort study cannot deliver.
Participating Institutes and Centers That Award Grants
National Heart, Lung, and Blood Institute (NHLBI)
NHLBI is interested in studies that:
Use data science and precision health to define individual heart, lung, blood, and sleep health signatures, including resilience metrics, stressors, tipping points, trajectories, and longitudinal outcomes across resistance, recovery, adaptation, and growth
Leverage large biomedical resources including NHLBI-funded cohort studies, Trans-omics for Precision Medicine (TOPMed), Researching COVID to Enhance Recovery (RECOVER), All of Us, and LungMap
Identify mechanisms that preserve, enhance, or restore homeostasis under stress and explain sustained health despite known risk, with the examples of hypertension without stroke, full recovery after heart valve surgery, preserved lung function despite tobacco exposure, and the interplay of resilience with sickle cell disease exacerbation such as vaso-occlusive crises
Integrate multidomain exposures and biopsychosocial factors such as mindfulness, belief systems, and optimism, alongside community engagement, and include all populations within the NHLBI mission
Contact: NHLBI Highlighted Topics (nhlbihighlightedtopics@mail.nih.gov).
The resource-leverage bullet is the most useful thing on this page for a cash-constrained company. Building and validating analytics on TOPMed, RECOVER, All of Us, or existing NHLBI cohorts means you are not funding new cohort collection out of a Phase I budget. That is the difference between a fundable aim and an unfundable one at $323,090, and it also gives your validation claims a credibility that a small proprietary dataset never will. The phrase "tipping points" is worth noticing too, since it points toward early-warning and state-transition detection, which is a defensible product category.
National Center for Complementary and Integrative Health (NCCIH)
NCCIH is interested in research advancing understanding of resilience as a whole-person, multilevel process that informs strategies for health promotion, disease prevention, recovery, and overall well-being across the lifespan. Areas of interest:
Identifying, validating, and promoting modifiable protective pathways and factors contributing to resilience across molecular, cellular, physiological, behavioral, psychological, social, and environmental domains
How complementary and integrative health approaches, lifestyle, and environmental factors affect the biological and behavioral mechanisms that enhance capacity to resist, recover, adapt, or grow
Mechanistic research to identify and validate measures and biomarkers of resilience, and to generate evidence supporting implementation of effective resilience-promoting strategies across populations and settings
NCCIH states it may give special consideration to support meritorious applications in this topic area.
Contacts: Erin Burke Quinlan, PhD and Jennifer Baumgartner (NCCIHDERFunding@nih.gov).
NCCIH matters disproportionately here for a reason that is not obvious from the topic page. Its standing small business portfolio already covers nutritional and natural products including dietary supplements and botanicals, psychological approaches such as meditation and music-based interventions, physical approaches including devices, and combined approaches such as yoga and tai chi. That makes NCCIH the natural funding home for several categories of resilience product that no other participating Institute would readily take, and the only one of the six signaling a preference alongside NIMHD.
National Cancer Institute (NCI)
NCI seeks projects advancing mechanistic understanding and interventions across cancer biology, prevention, and control, particularly studies that:
Develop, refine, or validate multilevel measures, biomarkers, and resilience signatures to defined stressors across cancer risk, tumor initiation, progression, treatment, and survivorship
Identify protective factors and mechanisms enabling resistance to malignant transformation or favorable outcomes despite genetic, environmental, behavioral, or biological risk, including but not limited to DNA repair, immune surveillance, microbiome and host interactions, epigenetic stability, inflammation resolution, and metabolic adaptability
Use advanced analytics in large, diverse longitudinal cohorts, and mechanistic studies in patients, human tissues, or model systems, to design, test, or implement interventions and strategies for risk stratification, early detection, prevention behaviors, treatment tolerance, and survivorship
Contact: NCI Resilience HT Team (NCIResilienceHTTeam@mail.nih.gov).
Note the phrase "resilience signatures to defined stressors." NCI has embedded the stressor requirement into its own bullet. Note also treatment tolerance, which is the most immediately commercial item in NCI's list: predicting which patients will tolerate a given regimen is a risk-stratification product with an obvious buyer, and it is framed here as resilience rather than toxicity prediction.
National Institute on Aging (NIA)
NIA's interests, as they relate to resilience in older individuals:
Development and validation of dynamic resilience measures using controlled perturbations and longitudinal monitoring
Advanced analytics for multisystem resilience phenotyping
The impact of age, early-life, psychosocial, and other factors on changes in neurobiological, molecular, cellular, physiological, social, and behavioral resilience mechanisms; how these factors individually and interactively influence severity of and recovery from stressors; and how dysregulation or modulation of these mechanisms, particularly in those with multiple contributors to impaired resilience, shapes aging-related clinical endpoints
Shared and tissue-specific pathways and mechanisms of inter-organ or system-level coordination
Mechanisms underlying sex differences
Therapeutic targets for, and mechanisms by which, interventions improve resilience and preserve or restore clinical outcomes in representative populations
Contact: Stacy Carrington-Lawrence, PhD (stacy.carrington-lawrence@nih.gov).
NIA's first two bullets are the clearest product specifications in the entire topic. A validated perturbation protocol plus a monitoring modality plus an analytic layer that outputs a multisystem resilience phenotype is a commercial instrument, not a research finding. NIA also carries the most favorable budget ceilings of any participating Institute, discussed below.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIAAA seeks research on mechanisms shaping alcohol use, alcohol-related outcomes, recovery, and resilience across biological, behavioral, psychological, social, and environmental levels, and states that priority goes to reproducible studies that identify protective pathways and biomarkers, explain heterogeneity, and inform prevention and intervention. Named areas:
Longitudinal lifespan cohort studies using multimodal AI to integrate biological, behavioral, and environmental data and identify resilience to alcohol use disorder and alcohol harms, including resistance, recovery, and adaptation, and influences such as inter-brain synchrony, social enrichment, peer context, sleep, and community and environmental factors
Reverse translational and New Approach Methodologies studies of cellular, molecular, and circuit mechanisms that promote resilience despite alcohol risk exposure
Integrative multiomic studies of heterogeneity in resilience to alcohol use disorder, emphasizing protective pathways, validated biomarkers, and standardized, reproducible measures
Contacts: Laura Kwako (laura.kwako@nih.gov) and Miri Gitik (miri.gitik@nih.gov).
NIAAA's standing small business priorities already include biosensors and wearables for real-time monitoring, digital health and telehealth platforms, diagnostic tools and biomarkers, and advanced data analytics using machine learning on large health datasets. The overlap with this topic's multimodal AI and biomarker bullets is close to exact, which makes NIAAA one of the more mechanically straightforward routes for a data or sensor company.
National Institute on Minority Health and Health Disparities (NIMHD)
NIMHD supports solutions-oriented biological, behavioral, clinical, and population science research focused on resilience among populations with health disparities, including:
Identifying novel biological, behavioral, social, and environmental mechanisms that shape resilience across the life course, and elucidating pathways that buffer or mitigate stress-related health effects
Developing measures, biomarkers, and scalable interventions that generalize across populations and community contexts
Applying community-engaged, systems science, data science, and translational approaches to advance resilience research and its real-world impact
Examining epigenetic processes, vagal nerve function, and environmental and biological interactions to identify mechanisms and clinical targets for resilience
Investigating relationships between psychological resilience and the onset, severity, and progression of health events, as well as recovery duration, quality, and long-term outcomes
NIMHD states it may dedicate available funds to support applications in this Topic area, depending on availability of funds, the number of meritorious applications, and competing ICO priorities, and separately that it may give special consideration to meritorious applications in this topic area.
Contact: Rada Dagher, PhD, MPH (Rada.dagher@nih.gov).
NIMHD is the only ICO in this topic making both statements, which makes it the strongest signal on the page. The word scalable in its second bullet is doing real work: NIMHD is asking for interventions that generalize and deploy, which is a commercial requirement rather than an academic one. Vagal nerve function is also named explicitly, which is a specific and measurable physiological target with existing device and wearable pathways.
Participating Offices That Do Not Award Grants
Five participating ICOs cannot fund your application. Their published interests are still worth reading, because they tell you what NIH leadership is prioritizing and because a well-aimed application can be responsive to an office's interest while being funded by an Institute. But you must land on an Institute's mission.
Office of Dietary Supplements (ODS). ODS seeks research on how dietary supplements, meaning oral interventions of vitamins, minerals, natural products, botanicals, fatty acids, proteins, amino acids, or other bioactive food constituents, affect physiological, metabolic, cognitive, and immune resilience across the lifespan. Studies using repeated measures and challenge-recovery designs to test whether supplements help resist, recover, adapt, or grow after aging-related, infectious, metabolic, psychosocial, or environmental stressors are emphasized. Specific interests include elucidating biological mechanisms or protective pathways through which supplements influence adaptive responses to physiological stressors; identifying and validating supplement exposure biomarkers associated with maintenance or recovery of physiological function, resistance to defined stressors, or adaptive capacity; and developing and validating ways to measure resilience in a dietary supplementation context. Contact: Adam J. Kuszak, PhD (ods-funding@od.nih.gov).
This is the most product-specific section on the entire NIH page, and ODS has no money. If you are a supplement, botanical, or nutraceutical company, the practical route is almost always NCCIH, whose small business program explicitly covers nutritional and natural products, or NIA if the framing is aging and older adults. Talk to ODS for scientific alignment, then talk to NCCIH or NIA about who would actually fund it.
Office of Research on Women's Health (ORWH). ORWH is interested in projects that advance resilience research across the life course relevant to women's health, including pregnancy, menopause, and aging; incorporate sex as a biological variable in resilience mechanisms, measures, biomarkers, and trajectories; and address sex differences in multidomain resilience, including through computational models, to support rigorous, generalizable prevention, treatment, and recovery strategies. Contact: Marquitta White, MS, PhD (orwhinfo@nih.gov).
The Office of Autoimmune Disease Research within ORWH (OADR-ORWH) is interested in the role of stressors on early immune changes in the prodromal phase of autoimmunity; resilience as an immunopreventative strategy for autoimmune disease; and utilizing federated data platforms to enhance pattern recognition in complex multiomic datasets, enabling deeper insight into the multimodal drivers of autoimmune disease pathogenesis and co-occurring autoimmune diseases. Contact: Victoria Shanmugam, MBBS, FRCP, FACR, CCD (oadrinfo@nih.gov).
The federated data platform bullet is a software specification, and prodromal autoimmunity is a diagnostics opportunity. Neither office can fund it. Sex differences in resilience mechanisms is a named NIA interest as well, which gives you a funding route for the ORWH angle.
Office of Disease Prevention (ODP). For this topic, ODP is particularly interested in projects testing interventions to promote health and well-being in individuals, families, communities, or populations facing biological, social, economic, or environmental challenges, and encourages research enhancing protective factors across the life course to prevent disease and disability, improve well-being, and reduce long-term disease burden. Contact: Valerie Robinson, PhD, MPhil, MHA (valerie.robinson@nih.gov).
Office of Behavioral and Social Sciences Research (OBSSR). Participating, with Janine Simmons, MD, as contact (OBSSRNews@mail.nih.gov).
Tribal Health Research Office (THRO). Participating, with Sheila Caldwell, PhD (throinfo@od.nih.gov) and Christopher Barnhart, PhD (christopher.barnhart@nih.gov) as contacts. Note that the topic's purpose statement names tribal communities explicitly as a population of interest.
Where Does a Small Business Actually Fit?
Be honest with yourself here: this is the most research-heavy of NIH's current Highlighted Topics, and a large share of what it describes belongs in an R01 rather than an SBIR. Mechanistic biology in model systems, secondary analysis of existing cohorts for scientific insight, and epidemiological characterization are not products. NIH SBIR and STTR awards fund research and development toward a commercially viable product or service.
That said, NIH named measures, metrics, biomarkers, and data interoperability as high-priority areas, and those are all things that get built and sold. The genuine openings:
Validated resilience measurement instruments. NIH says the field is limited by heterogeneous measures and asks for harmonized terminology, standardized protocols, and validated measures. A validated, licensable instrument, whether a clinical assessment, a digital measure, or a scored composite, is a real product with a real market, and NCCIH, NIMHD, NIA, and NCI all ask for measure development independently. Whoever produces the instrument the field standardizes on owns a durable position.
Controlled perturbation and challenge-recovery testing systems. NIA's leading bullet, and echoed by ODS. A standardized stressor protocol plus a monitoring modality plus a scoring output is an instrument. This is the clearest hardware and software opportunity in the topic.
Multisystem phenotyping analytics. NIA asks for advanced analytics for multisystem resilience phenotyping. NHLBI asks for health signatures including resilience metrics, tipping points, and trajectories. NIAAA asks for multimodal AI integrating biological, behavioral, and environmental data. Three Institutes, one product category.
Biomarker panels that predict recovery rather than risk. NIH asks for biomarkers that reflect or predict resilience. This is a distinct diagnostic category from disease-risk biomarkers, and the clinical use cases are concrete: who will tolerate this treatment, who will recover from this surgery, who will decompensate under this stressor. NCI names treatment tolerance directly. NHLBI names recovery after heart valve surgery.
Remote monitoring and wearables for longitudinal trajectory capture. Resist, recover, adapt, and grow are all trajectories, and trajectories require repeated measurement. Continuous monitoring is the enabling technology, and NIAAA's standing portfolio already funds wearables and biosensors.
Data interoperability and federated analysis platforms. NIH names data interoperability as a high-priority area, and OADR-ORWH names federated data platforms specifically. Software with a plausible route to institutional customers.
Scalable intervention delivery. NIMHD asks for scalable interventions that generalize across populations and community contexts, and it is the Institute most likely to dedicate funds. Digital and community-deployable intervention platforms fit here.
Supplement and natural product mechanisms and exposure biomarkers. ODS's full list, funded through NCCIH or NIA.
Vagal nerve function measurement or modulation. Named explicitly by NIMHD, with existing device and wearable pathways.
What Will Not Work
A risk-reduction product relabeled as resilience. Covered above, and it is the single most predictable failure here. NIH drew the line explicitly with the phrase "distinct from disease-risk reduction."
A wellness or mindfulness app with no defined stressor and no measurement. NIH's structural requirement is to define the challenge or stressor, the system, and the resilience outcome. An application that cannot name its stressor is not responsive, regardless of how well the intervention is described.
A cross-sectional study. All four resilience outcomes are trajectories. If your design measures once, it cannot detect resistance, recovery, adaptation, or growth.
A measure with no validation plan. The field's problem is that everyone has a measure and none of them agree. Producing another unvalidated instrument adds to the problem NIH is trying to solve. Validation against an independent criterion is the whole value proposition.
Two Strategic Notes
Use the existing data assets. NHLBI explicitly invites leveraging TOPMed, RECOVER, All of Us, LungMap, and NHLBI cohorts. NCI asks for advanced analytics in large, diverse longitudinal cohorts. NIAAA asks for longitudinal lifespan cohort studies. For a small business, this is the difference between a feasible Phase I and an impossible one, because you can develop and validate an analytic or a measure without funding primary data collection. It also strengthens the generalizability claim that reviewers will otherwise attack.
STTR deserves a hard look. NIH describes this topic as inherently interdisciplinary across molecular, cellular, physiological, psychological, social, community, and environmental levels, and NIMHD asks for community-engaged approaches. Very few small companies hold that range internally. Under STTR, a formal collaboration with a university or nonprofit research institution is required, at least 40 percent of the work is performed by the small business and at least 30 percent by the research institution, and the Principal Investigator may be primarily employed by either organization. If you need an academic cohort, a validated psychometric bench, or a community-engaged research partner to be credible, PA-27-102 is often the stronger application.
How Much Funding Would I Receive?
There is no funding amount attached to the Highlighted Topic itself. Budgets come from the parent announcement and from the Institute that funds you.
Under the current NIH SBIR and STTR parent announcements, standard guidelines provide:
Phase I: up to $323,090, typically over one to two years
Phase II: up to $2,153,927, typically over two to three years
Fast-Track: Phase I and Phase II in a single application and review
Direct to Phase II: available under SBIR for companies that have already established feasibility
Phase IIB (PA-27-101): follow-on funding beyond Phase II
Commercialization Readiness Pilot: late-stage, milestone-driven support, with amounts varying by Institute
Cost sharing is not required.
NIA Carries the Best Ceilings in This Topic
Among the six participating Institutes that award grants, NIA holds approval to exceed the standard caps in both of its lanes:
Up to $700,000 for Phase I and $3 million for Phase II for Alzheimer's disease and AD-related dementia projects
Up to $500,000 for Phase I and $2.5 million for Phase II for other projects within the NIA mission space
That second line is easy to miss and it matters. A resilience-in-aging project that has nothing to do with dementia still carries a Phase I ceiling roughly 55 percent above standard and a Phase II ceiling about 16 percent above standard. Given that NIA also published the two most product-shaped bullets in the entire topic, dynamic resilience measures using controlled perturbations and multisystem resilience phenotyping analytics, the combination of scope fit and budget headroom makes NIA worth a conversation even if aging is not your primary framing.
NCI supports CRP projects up to the SBA statutory maximum of $4,191,495, plus up to $500,000 for technical assistance. NIMHD operates under standard caps but is the only participating ICO signaling both possible dedicated funds and special consideration.
Full Institute-by-Institute budget detail is in our NIH SBIR program executive summary.
What Could I Use the Funding For?
Funds support research and development toward a commercially viable product or service aligned with the mission of a participating Institute. Allowable costs include personnel, materials, instrument and device development, assay development, software development, validation studies, analysis of existing datasets, intellectual property protection, and other direct R&D expenses.
Phase II, Phase IIB, and CRP funds may additionally cover scale-up, multi-site validation, regulatory preparation, and commercialization activities.
Clinical trial policy depends on the Institute. Among the participating Institutes that award grants, NCI, NHLBI, NIA, and NIMHD accept clinical trials through their small business programs, and several accept them through Phase IIB as well. Policy for NCCIH and NIAAA under the current parent announcement should be confirmed directly with program staff before you design around it. Note that challenge-recovery and controlled-perturbation studies in human participants may or may not meet the NIH definition of a clinical trial depending on design, and that determination affects which announcement track and which forms apply. This is a specific question worth putting to your program officer in writing.
What Is the Timeline?
Highlighted Topic dates
Posted: August 28, 2026
Expires: August 25, 2028
SBIR and STTR standard receipt dates (PA-27-100 and PA-27-102)
September 5, 2026. This falls on a Saturday, and Labor Day is Monday, September 7, so submissions are accepted through Tuesday, September 8, 2026.
January 5, 2027
April 5, 2027
September 5, 2027, which falls on a Sunday before Labor Day, so that cycle effectively closes Tuesday, September 7, 2027
January 5, 2028
April 5, 2028
Because the topic expires on August 25, 2028, April 5, 2028 is the last standard receipt date inside the active window, giving you six cycles in total. The September 2028 date falls just outside it. All applications are due by 5:00 PM local time of the applicant organization.
Review and award timeline for the September 2026 cycle
Scientific merit review: November 2026
Advisory council review: January 2027
Earliest project start date: April 2027
Review and award timeline for the January 2027 cycle
Scientific merit review: March 2027
Advisory council review: May 2027
Earliest project start date: July 2027
Review and award timeline for the April 2027 cycle
Scientific merit review: July 2027
Advisory council review: August 2027
Earliest project start date: December 2027
A policy change that matters for planning. NIH tightened its late application policy under NOT-OD-26-064, effective for due dates on or after May 25, 2026. Small business applications no longer receive the discretionary late submission window. Submit early enough to resolve eRA Commons validation errors before the deadline.
Practical planning guidance. Budget at least twelve weeks of lead time before your target due date, and more if your federal registrations are not complete. SAM.gov, UEI, the SBA Company Registry, eRA Commons, and Grants.gov registrations can take four to six weeks on their own and must all be finished before you can submit. For a first-time applicant, expect 120 to 200 hours of total effort.
Two topic-specific timing items. If your plan depends on access to an existing NIH data resource such as TOPMed, RECOVER, or All of Us, start the data access request early, since approval processes have their own timelines and reviewers will want evidence that access is secured rather than hoped for. And if your design involves community-engaged research, which NIMHD asks for, community partnership agreements and letters with defined roles cannot be assembled in the final two weeks.
Who Is Eligible to Apply?
Eligibility comes from the parent announcement, not from the topic. Applicants must be U.S. small business concerns that are:
Organized for profit with a place of business located in the United States
At or below 500 employees, including affiliates
More than 50 percent owned and controlled by U.S. citizens or permanent resident aliens, by qualifying U.S. entities, or by a combination
For STTR, the company must also have a formal collaboration with a U.S. research institution, with at least 40 percent of the work performed by the small business and at least 30 percent by the research institution.
Foreign organizations are not eligible, and foreign subawards and subcontracts are not permitted.
Are There Restrictions I Should Know About?
Only U.S. small business concerns are eligible; foreign organizations are not.
Applications involving foreign subawards or subcontracts will not be considered for funding.
Your application must be relevant to the mission of a participating Institute or Center that awards grants. For this topic that means NHLBI, NCCIH, NCI, NIA, NIAAA, or NIMHD. OBSSR, ODP, ODS, ORWH, and THRO do not award grants.
Duplicate or highly overlapping applications submitted under multiple HHS announcements are not permitted.
Companies must satisfy applicable SBA performance benchmark requirements, including the Phase I to Phase II transition rate benchmark and the Phase II commercialization rate benchmark for companies with substantial award histories.
Phase I generally requires at least 67 percent of the research effort to be performed by the small business; Phase II at least 50 percent. Consultant and contractual arrangements in Phase I are generally limited to roughly 33 percent of the total amount requested, which is a real constraint if your design leans heavily on an academic cohort or a community partner. STTR is the cleaner structure in that case.
Additional national security, foreign relationship, and foreign ownership disclosure requirements apply and may result in denial of award. The 2026 SBIR and STTR reauthorization tightened foreign risk management and due diligence review, and that screening now sits inside the review critical path.
Cost sharing is not required.
Applying under a Highlighted Topic does not change referral or review, and does not guarantee that funds have been set aside.
What Kind of Application Is Likely to Win Here?
NIH reviews small business applications on Significance, Investigators, Innovation, Approach, and Environment, with commercialization potential specifically evaluated for Phase II and Fast-Track. Within this topic, five things separate competitive applications.
One: you named the stressor. NIH gave the structure explicitly: define the challenge or stressor, the systems, and the resilience response or outcome, and include at least one domain of analysis. Most weak resilience applications fail at the first item. Put the stressor in your Specific Aims page, not buried in the approach.
Two: you picked one of the four verbs and measured it. Resistance, recovery, adaptation, and growth are different phenomena with different measurement requirements. Specificity here reads as rigor. Gesturing at resilience generally reads as vagueness.
Three: you are not doing risk reduction in a new coat. NIH said "distinct from disease-risk reduction." Your work should explain or enhance maintained health in the continued presence of risk.
Four: you picked the right Institute, and you picked it before writing. Six Institutes could plausibly claim a resilience measurement product, and five participating offices cannot fund it at all. This topic has more misrouting risk than any other current Highlighted Topic. Email the named contact, describe the technology in a paragraph, and ask whether it fits and which mechanism they would suggest. For supplement and natural product work specifically, ask ODS about science and NCCIH or NIA about funding.
Five: your validation plan is the centerpiece, not an afterthought. NIH's stated problem is heterogeneous measures and lack of reproducibility, and NIAAA states outright that priority goes to reproducible studies. Whatever you build, the aim that matters is the one where you validate it against an independent criterion in a population that looks like the intended market.
Frequently Asked Questions
Is the NIH multidomain resilience Highlighted Topic a funding opportunity I can apply to directly?
No. An NIH Highlighted Topic is a published statement of scientific priority, not a Notice of Funding Opportunity. There is no application package and no separate deadline. Small businesses apply through a broad NIH opportunity, which means the SBIR parent announcement PA-27-100 or the STTR parent announcement PA-27-102.
How does NIH define resilience for this topic?
NIH defines resilience broadly as a living system's capacity to resist, recover, adapt, or grow from challenges or stressors, with outcomes tracked over time across interconnected individual, community, and environmental systems. NIH attributes this framing to Brown and colleagues, 2023. The four outcomes are distinct: resistance means function is maintained through the stressor, recovery means function returns to baseline, adaptation means the system reorganizes to a new functional state, and growth means it ends up better than before.
What does NIH require an aligned application to include?
NIH states that aligned applications would define the challenge or stressor, define the system or systems, define the resilience response or outcome, and include at least one domain of analysis, preferably across domains, in order to accelerate translation into implementable prevention, treatment, and recovery strategies. Failing to specify the stressor is the most common way a resilience application loses responsiveness.
How much funding is available under this Highlighted Topic?
The topic itself carries no funding amount. Standard SBIR guidelines provide up to $323,090 for Phase I and up to $2,153,927 for Phase II. Among the participating Institutes, NIA holds approval to exceed those caps, allowing up to $700,000 for Phase I and $3 million for Phase II on Alzheimer's disease and AD-related dementia projects, and up to $500,000 for Phase I and $2.5 million for Phase II for other projects in its mission space. NCI supports Commercialization Readiness Pilot projects up to the SBA statutory maximum of $4,191,495 plus up to $500,000 for technical assistance.
Does applying under this Highlighted Topic improve my chances of being funded?
Not in review. NIH states that applying in a Highlighted Topic area will not affect referral or review of applications. NIMHD states it may dedicate available funds to this topic area and may give special consideration to meritorious applications in it, and NCCIH states it may give special consideration. The other participating ICOs make no such statement. The main advantage is informational.
Which NIH Institutes and Centers participate, and which ones can actually fund my application?
Eleven ICOs participate. Six award grants: NHLBI, NCCIH, NCI, NIA, NIAAA, and NIMHD. Five do not: OBSSR, ODP, ODS, ORWH including the Office of Autoimmune Disease Research, and THRO. Your application must be relevant to the mission of at least one of the six that award grants.
I work on dietary supplements and the Office of Dietary Supplements published detailed interests. Can ODS fund my SBIR?
No. ODS does not award grants, despite publishing the most product-specific interests in this topic, including supplement exposure biomarkers and challenge-recovery designs testing whether supplements help resist, recover, adapt, or grow. The practical route is NCCIH, whose small business program explicitly covers nutritional and natural products including botanicals, or NIA if the framing is aging and older adults. Discuss science with ODS and funding with NCCIH or NIA.
What are the application deadlines?
The topic is open from August 28, 2026 through August 25, 2028. SBIR and STTR standard receipt dates are September 5, 2026, January 5, 2027, April 5, 2027, September 5, 2027, January 5, 2028, and April 5, 2028. Because the topic expires in August 2028, April 5, 2028 is the last standard receipt date inside the active window. September 5, 2026 falls on a Saturday before Labor Day, so that cycle accepts submissions through Tuesday, September 8, 2026, and September 5, 2027 falls on a Sunday before Labor Day, so that cycle closes Tuesday, September 7, 2027. All applications are due by 5:00 PM local time of the applicant organization.
What is the difference between resilience research and disease-risk reduction?
NIH explicitly asks for mechanistic understanding of protective and restoring factors distinct from disease-risk reduction. Lowering a risk factor reduces exposure to risk. Resilience explains or enhances maintained health in the continued presence of risk. NHLBI's examples make the distinction concrete: hypertension without stroke, preserved lung function despite tobacco exposure, and full recovery after heart valve surgery. Repackaging an existing risk-reduction product as resilience-promoting is visible to reviewers.
What kinds of resilience projects fit NIH SBIR rather than a research grant?
The strongest small business fits are validated resilience measurement instruments, controlled perturbation and challenge-recovery testing systems paired with longitudinal monitoring, multisystem phenotyping analytics, biomarker panels that predict recovery capacity rather than disease risk, remote monitoring and wearables for trajectory capture, data interoperability and federated analysis platforms, scalable intervention delivery, supplement and natural product exposure biomarkers, and vagal nerve function measurement or modulation. Mechanistic biology in model systems and secondary cohort analysis for scientific insight generally belong in an R01 instead.
Can I use existing NIH datasets instead of collecting new data?
Yes, and NIH encourages it. NHLBI explicitly invites leveraging its cohort studies, TOPMed, RECOVER, All of Us, and LungMap. NCI asks for advanced analytics in large, diverse longitudinal cohorts. For a Phase I budget this is often the difference between a feasible and an infeasible aim, and it strengthens generalizability claims. Start data access requests early, because approval has its own timeline and reviewers want evidence access is secured.
Why do NIA and ODS emphasize controlled perturbations and challenge-recovery designs?
Because resistance, recovery, adaptation, and growth are all trajectories, and a cross-sectional measurement cannot capture a trajectory. A stressor must be applied or occur, with the system measured before, during, and after. For companies this is favorable, since instrumentation, wearables, remote monitoring, and analytics are precisely what these designs require and precisely what an observational cohort cannot deliver.
Should my company apply for SBIR or STTR?
Choose SBIR if your company performs the majority of the research and your Principal Investigator is primarily employed by the company. Choose STTR if the project depends on a formal collaboration with a university or nonprofit research institution. Because NIH describes this topic as inherently interdisciplinary across molecular, physiological, psychological, social, community, and environmental levels, and because NIMHD asks for community-engaged approaches, STTR is frequently the stronger structural fit. Phase I SBIR generally limits consultant and contractual arrangements to roughly 33 percent of the total requested, which constrains designs that lean heavily on academic or community partners.
Can I run a clinical trial with this funding?
It depends on the Institute. Among the participating Institutes that award grants, NCI, NHLBI, NIA, and NIMHD accept clinical trials through their small business programs, and several accept them through Phase IIB as well. Confirm NCCIH and NIAAA policy directly with program staff. Note also that challenge-recovery and controlled-perturbation studies in human participants may or may not meet the NIH definition of a clinical trial depending on design, and that determination affects which forms and which track apply, so put the question to your program officer in writing.
Who is eligible to apply?
For-profit U.S. small business concerns with 500 or fewer employees including affiliates, more than 50 percent owned and controlled by U.S. citizens or permanent residents or by qualifying U.S. entities. Foreign organizations are not eligible, and foreign subawards and subcontracts are not permitted. STTR additionally requires a formal collaboration with a U.S. research institution.
How long will it take me to prepare an application?
For a first-time applicant, expect 120 to 200 hours in total. Start at least twelve weeks before your target due date. Federal registrations across SAM.gov, UEI, the SBA Company Registry, eRA Commons, and Grants.gov can take four to six weeks on their own and must be complete before you can submit.
What happens if I submit late?
It will not be accepted. NIH tightened its late application policy for due dates on or after May 25, 2026, and small business applications no longer receive the discretionary late submission window.
Could this Highlighted Topic be withdrawn before it expires?
Possibly. NIH reviews each Highlighted Topic annually for continued alignment with agency priorities, and Institutes can post and retire topics at any time. The posted expiration date is August 25, 2028, but verify the topic is still live before each cycle you plan to submit in.
How Can BW&CO Help?
BW&CO is a non-dilutive federal funding advisory firm. We have helped clients secure more than $350 million in federal funding, and this topic is a good example of where advisory work earns its keep: eleven participating ICOs, only six of which can fund anything, the two most product-specific bullet lists belonging to offices with no money, a definitional line between resilience and risk reduction that reviewers will enforce, and one Institute quietly carrying budget ceilings well above the standard caps.
We can:
Identify the right Institute and mechanism for your technology, including routing supplement, natural product, women's health, autoimmune, and federated data platform concepts to an Institute that can actually fund them.
Structure the application around NIH's own checklist, so the stressor, the system, the resilience outcome, and the domains of analysis are unmistakable on the Specific Aims page.
Triple your likelihood of success through proven strategy and insider-aligned proposal development.
Reduce your time spent on the proposal by 50 to 80 percent, so your team stays on the technology.
Structure academic, cohort, and community partnerships so they strengthen the application without breaching the outsourcing limits.
